• Eng
  • 한국어

    • Company
    introduction

    ICM pursues novel therapeutic solutions
    for incurable diseases

    Company

    History

    We are committed to restore and improve the lives of
    suffering patients by delivering novel therapeutic solutions.

    • 2024
      • Korea Drug Development Funding
      • ICM-502 Licensing Out(Global Pharma)
    • 2022
      • ICM-203 FDA P1/2a IND approval
    • 2021
      • Pre-IPO (KRW 21 billion) closed
      • Initiated Phase1/2a global clinical trial for ICM-203
    • 2020
      • Completion of ICM-203 GMP Production
      • Completion of ICM-203 GLP Tox/BD Study
      • Winner of Yonsei University
        Grand-Prize for Faculty Start-up
    • 2018
      • Qualified as a Military Service Designation Company by Ministry of National Defense
    • 2017
      • Series B (KRW 6 billion) closed
    • 2016
      • Series A (KRW 5 billion) closed
      • Venture Company Certification by Korea Venture Capital Association
    • 2015
      • Corporate R&D Center
        Certification from KOITA
    • 2012
      • Industry-Academy Joint-Venture Support Program (Ministry of Education and Science Technology)
      • Establishment of ICM Co., Ltd.
      • New Drug Candidate Optimization Support Program (Ministry of Science, ICT and Future Planning)